HighTower Advisors’s CorMedix CRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$205K Sell
30,179
-1,176
-4% -$8.69K ﹤0.01% 3464
2025
Q4
$365K Buy
31,355
+355
+1% +$3.92K ﹤0.01% 2877
2025
Q3
$361K Buy
31,000
+3,000
+11% +$36.3K ﹤0.01% 2885
2025
Q2
$345K Sell
28,000
-1,138
-4% -$12.6K ﹤0.01% 2810
2025
Q1
$179K Hold
29,138
﹤0.01% 3225
2024
Q4
$236K Buy
29,138
+9,566
+49% +$95.5K ﹤0.01% 3072
2024
Q3
$158K Buy
19,572
+434
+2% +$2.35K ﹤0.01% 3210
2024
Q2
$83K Hold
19,138
﹤0.01% 3238
2024
Q1
$81K Hold
19,138
﹤0.01% 3191
2023
Q4
$73K Hold
19,138
﹤0.01% 3252
2023
Q3
$71K Sell
19,138
-17,250
-47% -$68.6K ﹤0.01% 3176
2023
Q2
$145K Buy
36,388
+17,250
+90% +$85.3K ﹤0.01% 2977
2023
Q1
$79K Hold
19,138
﹤0.01% 2984
2022
Q4
$80K Hold
19,138
﹤0.01% 2966
2022
Q3
$54K Hold
19,138
﹤0.01% 2869
2022
Q2
$77K Buy
19,138
+5,000
+35% +$18.6K ﹤0.01% 2841
2022
Q1
$78K Sell
14,138
-1,500
-10% -$6.87K ﹤0.01% 3026
2021
Q4
$72K Buy
15,638
+1,500
+11% +$7.45K ﹤0.01% 2984
2021
Q3
$66K Hold
14,138
﹤0.01% 2908
2021
Q2
$97K Hold
14,138
﹤0.01% 2818
2021
Q1
$141K Sell
14,138
-2,200
-13% -$23.2K ﹤0.01% 2691
2020
Q4
$121K Buy
+16,338
New +$111K ﹤0.01% 2315
2019
Q1
Sell
-7,438
Closed -$48K 2316
2018
Q4
$48K Sell
7,438
-2,200
-23% -$14.7K ﹤0.01% 2032
2018
Q3
$47K Buy
9,638
+200
+2% +$492 ﹤0.01% 2128
2018
Q2
$11K Hold
9,438
﹤0.01% 2136
2018
Q1
$9K Buy
9,438
+2,000
+27% +$3.99K ﹤0.01% 2089
2017
Q4
$19K Sell
7,438
-6,000
-45% -$17.2K ﹤0.01% 2161
2017
Q3
$35K Hold
13,438
﹤0.01% 2102
2017
Q2
$29K Buy
13,438
+4,000
+42% +$13.7K ﹤0.01% 2051
2017
Q1
$77K Buy
9,438
+3,000
+47% +$28.6K ﹤0.01% 1893
2016
Q4
$49K Hold
6,438
﹤0.01% 1815
2016
Q3
$81K Buy
6,438
+1,000
+18% +$9.35K ﹤0.01% 1755
2016
Q2
$54K Sell
5,438
-563
-9% -$8.57K ﹤0.01% 1640
2016
Q1
$80K Buy
6,001
+2,001
+50% +$19.4K ﹤0.01% 1930
2015
Q4
$41K Buy
4,000
+2,000
+100% +$23K ﹤0.01% 1902
2015
Q3
$20K Buy
+2,000
New +$30.8K ﹤0.01% 1828

Other funds holding CRMD

HighTower Advisors's CRMD Position: Q1 2026 in Review

HighTower Advisors reduced its CorMedix (CRMD) stake by 3.8% in Q1 2026, selling an estimated $8.69K and leaving 30,179 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #3464.

HighTower Advisors first reported a position in CRMD in Q3 2015 and has held it in 36 quarters since. The position peaked at $365K in Q4 2025. 187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

  • HighTower Advisors held 30,179 shares of CorMedix worth $205K as of Q1 2026.
  • HighTower Advisors sold 1,176 CorMedix shares in Q1 2026, an estimated $8.69K.
  • CorMedix made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3464 holding.
  • HighTower Advisors first reported a position in CorMedix in Q3 2015 and has held it in 36 quarters since.
  • HighTower Advisors's CorMedix position peaked at $365K in Q4 2025.
  • 187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.